
FIG. 1



Concentration (μm)

FIG. 2




Cytokine/Chemokine Production
% of Control
(mean ± SEM)
1000
800
600
400
200
0
0.00001
0.0001
0.001
0.01
0.1
1
10
100
Concentration (μm)
IL-13
IL-5
GM-CSF
IL-3
IFN-gamma
IL-17A
RANTES
TNF-alpha
IL-10

FIG. 3



Concentration (μm)

FIG. 4



Cytokine Production
(mean % of control)
600
500
400
300
200
100
0
0.00001
0.0001
0.001
0.01
0.1
1
10
IL-10
MCP-1
RANTES
Concentration (μm)

FIG. 5



IFN-γ Production (pg/mL)
3000
2400
1800
1200
600
0
0
0.0001
0.001
0.01
0.1
1.0
10
Concentration (μm)

FIG. 6



IFN-γ Production
(Percentage of IFN-γ Produced with 1μM Pomalidomide)
120
90
60
30
0
0
0.0001
0.001
0.01
0.1
1.0
10
Concentration (μM)

FIG. 7



% cytotoxicity
Rituximab alone
Farage
WSU-DLCL2
DoHH2
Riva
Raji
0
0.001
0.01
0.1
1.0
10
Concentration (μm)

FIG. 8







FIG. 9


NaCl
Bleomycin 3 w + NaCl 3 w
Bleomycin 6 w
Test compound (30 mg/kg)
Imatinib (50 mg/kg)